GlassScriptPhysician profile
Kristin Pass
NPI 1750796561
$6,284.80
in general payments reported to CMS, 2019-2025
40 companies · $1,981 in 2025
The $1,981 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $625 · 2023: $1,451 · 2024: $1,746 · 2025: $1,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,078 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,078.03 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $861.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $572.93 | 2021-2025 | |
| Pfizer INC. | $545.27 | 2021-2025 | |
| Gilead Sciences, INC. | $508.18 | 2022-2025 | |
| Novo Nordisk INC | $425.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $273.91 | 2022-2025 | |
| Glaxosmithkline, LLC. | $240.67 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $228.28 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $214.23 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.74 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Merck Sharp & Dohme LLC | $198.16 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Astellas Pharma US INC | $196.48 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $191.57 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $159.04 | 2022-2025 | Rexulti, Jynarque |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.61 | 2021-2025 | Xifaxan, Trulance |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $126.05 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $121.28 | 2023-2024 | |
| Inspire Medical Systems, INC. | $102.88 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $95.96 | 2021-2024 | Trintellix |
| Abbott Laboratories | $87.61 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $85.16 | 2021 | |
| Phathom Pharmaceuticals, INC. | $67.02 | 2024-2025 | Voquezna |
| Viiv Healthcare Company | $65.34 | 2023-2025 | Apretude |
| Dexcom, INC. | $59.45 | 2022-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $58.97 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $54.18 | 2021-2023 | Spravato |
| Noven Therapeutics, LLC | $47.43 | 2024 | Xelstrym |
| Verity Pharmaceuticals INC. | $43.91 | 2024 | Tlando |
| Currax Pharmaceuticals LLC | $41.51 | 2024-2025 | Contrave |
| Sanofi Pasteur INC. | $39.57 | 2022-2023 | |
| Hologic Sales and Service, LLC | $34.27 | 2022-2023 | Aptima |
| Acadia Pharmaceuticals INC | $31.52 | 2025 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $28.60 | 2021 | |
| Dynavax Technologies Corporation | $27.48 | 2024 | Heplisav-B |
| Tris Pharma INC | $23.81 | 2024 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $22.93 | 2022 | |
| Shield Therapeutics INC | $20.03 | 2023 | Accrufer |
| Amgen INC. | $18.54 | 2024 | Evenity, Prolia |
| Paratek Pharmaceuticals, INC. | $15.71 | 2021 | |
| Radius Health, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Pass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.